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To test the hypothesis that mononuclear cell products
could increase the expression of HLA-DR and ICAM-1
molecules in bronchial epithelial cells (BECs),
subconfluent cultures of human BECs, obtained from
surgically resected bronchi, were incubated with PHA-
activated blood mononuclear cell conditioned media
(BCM-CM) or recombinant IFN-T. The presence ofHLA-DR
and ICAM-1 molecules on BECs was then evaluated by
specific antibody staining and flow-cytometry analysis.
The addition to BEC cultures of different concentrations
of PHA-stimulated BMC-CM, or of IFN-% induced a dose-
dependent increase of HIA-DR and ICAM-1 expression,
while no effectwas observed with unstimulated BMC-CM.
The ability of nedocromil sodium and, as control, of
dexamethasone, to prevent the upregulation of HLA-DR
and ICAM-1 expression on BECs was then tested. Increas-
ing concentrations (10-7 to 10-4 M) of nedocromil signifi-
candy inhibited HLA-DR and ICAM-1 expression by BECs
in a dose-dependent fashion. A similarly dose-dependent
inhibitory effect was also observed with dexamethasone,
which, however, was less active than nedocromilon HI.A-
DR expression and more active on ICAM-1 expression.
Finally, nedocromil and dexamethasone showed a sig-
nificant synergistic effect on the expression of both cell
surface molecules at the lowest concentrations tested.
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Introduction
The airway epithelium, as well as acting as a barrier
between the outside and inside environment, also
appears to have important metabolic and immuno-
logical properties. In this context, bronchial
epithelial cells can actively release a range of media-
tors which participate in inflammatory and healing
processes and which modulate immune responses
within the lung. The development of any inflamma-
tory response depends upon efficient antigen pres-
entation to relevant leukocytes, the mobilization of
these cells to the inflammatory site, and their attach-
ment to the target cells, all of these steps being
dependent on cell-to-cell contact. A basic mechanism
for cellular interaction involves the expression of
class II human leukocyte antigens (HLA), such as
HLA-DR. These major histocompatibility (MCH) class
II gene products have a functional role in guiding
helper T-cells in the recognition of extrinsic antigens
and in the subsequent initiation of an immune re-
sponse. HLA-DR molecules are expressed constitu-
tively by B cells, activated T-cells, dendritic cells,
macrophages and, at lower levels, by other cell types,
such as endothelial and some epithelial cells, and
their expression can be induced or increased by
inflammatory stimuli, including cytokines. A further
mechanism allowing close cell-to-cell contact is
dependent upon the expression of cell adhesion
proteins, such as the intercellular adhesion
molecule-1 (ICAM-1 or CD54), which belongs to the
immunoglobulin superfamily. ICAM-1 is constitu-
tively expressed by only a few cell types,
5,8 but its
expression can be specifically upregulated by inflam-
matory mediators such as interferon-, (IFN-T),
interleukin-1 (IL-1), and tumour necrosis factor-or
(IFN-00. 5,7 Thus, it can .be hypothesized that cells
involved in inflammatory processes may express in-
creased levels of HLA-DR and ICAM-1. Moreover, an
increased expression of both HLA-DR and ICAM-1
molecules by bronchial epithelial cells has been
reported in asthma and chronic bronchitis, and the
extent of the expression of these markers seems to
correlate with clinical parameters. Since both asthma
and chronic bronchitis are disorders characterized by
the presence of activated mononuclear cells in the
bronchial structures,
1 the present study was de-
signed to evaluate whether mononuclear cells could
increase the expression of HLA-DR and ICAM-1
molecules on bronchial epithelial cells. After this
hypothesis proved to be correct, we tested the ability
of nedocromil sodium (Tilade, Fisons plc, Lough-
borough, England), a topical anti-inflammatory drug
used in patients with inflammatory airway disorders,
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and of a steroid, dexamethasone, to prevent the
upregulation of HLA-DR and ICAM-1 expression in
cultured human bronchial epithelial cells.
Methods
Reagents: Laboratory of human carcinogenesis (LHC)
basal medium, fetal calf serum (FCS),
triiodothyronine (T3), hydrocortisone, and
epinephrine were purchased from Biofluids Inc.
(Rockville, MD, USA). RPMI-1640 (RPMI), phosphate
buffered saline (PBS), DME, MEM, Hank’s balanced
salt solution (HBSS), streptomycin-penicillin, Ficoll,
non-essential aminoacids, t-glutamine, trypan blue
dye and fungizone were obtained from Flow ICN
(Irvine, UK). Insulin, transferrin, bacterial type XIV
protease, 2-mercaptoethanol, phytohaemoagglutinin
(PHA), sodium azide and retinoic acid were pur-
chased from Sigma Chemical Co. (St Louis, MO,
USA). Phosphoethanolamine/ethanolamine, trace
elements (selenium, manganese, molybdenum, va-
nadium, nickel, tin) and calcium were obtained from
Fischer Scientific Co. (Pittsburgh, PA, USA). Frozen
bovine pituitaries were obtained from Pel-Freez
Biologicals (Rogers, AR, USA), and bovine type
collagen (Vitorgen 100) was obtained from Collagen
Corp. (Palo Alto, CA, USA). Nedocromil sodium, as
a pure powder, was a gift from Fisons Italchimici
(Roma, Italy), dexamethasone was obtained from
Collaborative Research Inc. (Bedford, MA, USA).
Human recombinant IFN-y was purchased from
Technogenetics (Milano, Italy).
Blood mononuclear cells collection: Heparinized
blood samples from three healthy donors were di-
luted 2:3 HBSS plus 0.35 g/1 sodium bicarbonate,
without calcium and magnesium. In order to isolate
peripheral blood mononuclear cells (BMC), blood
samples were layered on top of Ficoll gradients and
centrifuged for 20 min at 1500 g, as described. 11 The
BMC layer at the Ficoll interface (70-80%
lymphocytes and 20-30% monocytes as determined
by differential cell count) was gently aspirated and
the cells washed, counted and resuspended at the
desired density in complete medium (RPMI supple-
mented with 10% autologous serum, 2 g/1 NaHCO3,
50 U/ml penicillin, 50 l.tg/ml streptomycin, 2 mM
t-glutamine, non-essential aminoacids and 5 mM
2-mercaptoethanol), The cells thus recovered were
98% viable, after a trypan blue dye exclusion test.
Mononuclear cells stimulation: The BMCs, 106 cells/
ml, were incubated at 37C in 5% Co2 with or without
PHA (0.5 mg/ml). After three days, the supernatants
were collected and stored at-80C to be used later
as condition medium (BMC-CM) in human bronchial
epithelial cell (BEC) cultures, while the BMC were
resuspended in complete medium plus 2.25 t.tl/ml of
tritiated thymidine. After 18 h, the cells’ proliferative
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response to PHA was assessed by measuring the 3HT
uptake with a Beta counter.1 Control wells included
BMC cultures in complete medium, without mitogen.
Human bronchial epithelial cells isolation: Bronchial
epithelial cells were prepared by a modification of
the method described by Wu and colleagues,
2 as
previously described. 13 Human bronchi, obtained at
the time of surgical procedures, were trimmed of
lung parenchyma and peribronchial vascular struc-
tures, and incubated at 4C overnight in sterile
calcium-free Eagle’s MEM containing 0.1% bacterial
protease (type XlV). The bronchial lumens were then
gently rinsed several times with MEM containing 10%
FCS to detach the epithelial cells. The collected cells
were washed once in the same medium, filtered
through one layer of surgical sterile gauze and
washed twice with MEM. The cell count was manu-
ally determined using a standard haemocytometer.
Extensive evaluation of cells prepared by this
method has shown that > 95% of the harvested cells
are epithelial cells (cytocheratine positive).
14
In vitro human bronchial epithelial cells culture: BEC
were plated for growth at 37C in 5% CO2 in 100mm
tissue culture plates (Becton Dickinson, Lincoln Park,
NJ, USA) previously coated with bovine type colla-
gen. LHC basal medium5 was used, supplemented
with 5 lag/ml insulin, 10 t.tg/ml transferrin, 10 nM T3,
0.2 btM hydrocortisone, 0.33 nM retinoic acid, 5 t.tM
phosphoethanolamine/ethanolamine, trace ele-
ments, 0.11 mM calcium, bovine pituitary extract16
containing 10 mg/ml of protein (0.5%), 50 btg/ml
penicillin-streptomycin, and 2 btg/ml fungizone. The
LHC-supplemented medium was mixed 1:1 with
RPMI, a solution that has been found to optimize
BEC growth. In the average cell preparation, 20-30%
of the viable cells plated at the start of the culture
were attached to the tissue culture plates after 24 h
and about a quarter of the adherent cells were able
to proliferate. Because the confluent epithelial cells
tend to assume a squamoid shape when replated and
are less responsive to cytokines (O. Sacco, personal
observation), the growing epithelial cells were con-
tinuously maintained in a sub-confluent state by
replating the cells every 3-4 days.
Blood mononuclear cell condition medium and
IFN-g effect on HLA-DR and ICAM-1 expression: For
the experiment, 30-40 103 BEC/well were plated in
24-well tissue culture plates and stimulated with
cytokines after 24 h. BMC-CM and human
recombinant IFN-y were used to evaluate the
effects of a lymphocyte-derived cytokine on the
expression of HLA-DR and ICAM-1 by BEC. In some
experiments, BEC cultures were exposed to in-
creasing concentrations of the BMC-CM or human
recombinant IFN-y. For control cultures, equivalent
concentrations of 10% FCS in RPMI-1640 were added.Nedocromil sodium downregulates HLA-DR and ICAM-I expression
In some experiments, to test in vitro a possible
inhibitory effect of corticosteroids and cromones on
bronchial epithelial cell activation, bronchial
epithelial cells were also exposed to dexamethasone
and nedocromil sodium, at concentrations ranging
from 10-4 to 10-9 M. For experiments performed with
nedocromil and dexamethasone alone or together,
bronchial epithelial cells were activated with 0.5%
PHA-stimulated BMC supernatant, and the two drugs
were added at the same time separately or together
with the BMC stimulating supernatant. BECs were
harvested for fluorescence study 36 h after exposure
to BMC-CM.
Evaluation of surface antigen expression: The sur-
face expression of HLA-DR and ICAM-1 was evalu-
ated by specific antibody staining and flow-
cytometry analysis. The BEC were trypsinized 36 h
after stimulation with the BMC-CM, and then washed
in MEM and resuspended in the staining medium
which contained 1% fetal calf serum and 0.2% so-
dium azide in PBS. HBEC suspensions were placed
into round-bottom microtitre 96 well/plates (Costar
Corp., Cambridge, MA., USA) and incubated for 60
min at 4C in 50 1 of the staining medium with a
monoclonal antibody to human HLA-DR fluorescein
isothiocyanate (FITC)-conjugate (Technogenetics,
Milan, Italy) or a monoclonal mouse antibody anti-
human ICAM-1 (CD54) (Sera Lab, Crawley Down,
UK). A monoclonal antibody against human plate-
lets, PTF 19, was used as a negative control prepara-
tion. 11 The cells stained with the anti-HLA-DR-FITC
conjugated antibody were washed three times with
staining medium, then fixed in PBS plus 1%
paraformaldehyde (Eastman Kodak Co., Rochester,
NY, USA). The cells incubated with the anti-ICAM-1
antibody were washed twice, stained with a goat
anti-mouse-FITC conjugated antibody (Techno-
genetics srl, Milan, Italy) and then fixed as previously
described. The cells were analysed by single colour
immunofluorescence flow cytometry (FACS scan,
Becton Dickinson Immunocytometry Systems,
Mountain View, CA, USA). To compare the fluores-
cence intensities of different samples from the same
experiments, the analyses were performed with iden-
tical settings of the logarithmic amplifier, and
listmode files were analysed with Lysis II software
(Becton Dickinson). After conversion to linear fluo-
rescence intensity units to obtain a linear function or
fluorescence intensity units over a wide range,
16 the
average background linear fluorescence obtained
with the control antibody level could be subtracted
from the average fluorescence intensity of the specifi-
cally stained cells. The possible changes in cell size
in the different experimental conditions were con-
trolled by means of the forward light scatter signal of
the flow cytometer, proportional to cell size and
algebraically adjusted for increases in cell surface
area, so that the intensity in relative linear fluores-
cence units could be obtained. 17 This correction al-
lows the average fluorescence intensity to be directly
correlated with the cell surface density of the stained
antigens. All experiments were performed three
times. To compare the drug downregulating effect on
the expression of HLA-DR and ICAM-1 in different
cell cultures, the average fluorescence intensity was
transformed into relative fluorescence (control stimu-
lated cells 100% of relative fluorescence) and the
drug effect was expressed as the percentage inhibi-
tion of the relative fluorescence.
100 (100 x average fluorescence of the sample)
drug effect
average fluorescence of the control stimulated cells
Statistical analysis: All data are expressed as arithme-
tic mean + standard error of the mean. Analysis of
variance (ANOVA) was used to compare the potency
of various concentrations of the drugs tested. The
mean values were said to be statistically significant
when the probability of the event was below 5%
(p < 0.05).
Results
HLA-DRandICAM-1 expression byhuman bronchial
epithelial cells: Control BEC, growing in LHC me-
dium, show negligible basal expression of HLA-DR
and ICAM-1 antigens. When incubated with human
recombinant IFN-, for 36 h at concentrations of 5, 10,
50, 200 and 1000 U/ml, the expression of the two
surface molecules was enhanced in a dose-depend-
ent manner (Fig. 1A and 1B). Similarly, the addition
of different concentrations of BMC-CM (0.5, 1 and
3%) to BEC induced, after 36 h, a dose-dependent
increase of HLA-DR (Fig. 1) and ICAM-1 expression
(Fig. 2), while the supernatant from the control
(unstimulated BMCs) had no effect on the cell sur-
face antigen expression. The relative fluorescence
intensity related to the intensity of HLA-DR molecule
expression showed a similarly close correlation with
the concentration of IFN-,(p < 0.01) and of the PHA-
stimulated BMC-CM (p < 0.01) (Fig. 1). Using human
recombinant IFN-7 as standard, we calculated that the
IFN-,-like activity in the BMC-CM was equivalent
to 1.46 + 0.54 units/btl of the human recombinant
IFN-,. A weaker correlation was found between
the relative fluorescence intensity related to ICAM-1
molecule expression and either the concentration of
IFN-, (p<0.05) or the BMC-CM concentration
(p < 0.05) (Fig. 2).
Pharmacologic inhibition ofHLA-DR expression on
bronchial epithelial cells: When added to the BEC
cultures at the same time as BMC-CM, nedocromil
(10-4 tO 10-9 ) was able to inhibit the expression of
HLA-DR on BEC in a dose-dependent manner (Fig.
3) at all the concentrations tested, and the effect was
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FIG. 1. Expression on human bronchial epithelial cells of HLA-DR surface antigens after 24 h incubation with medium alone (control
supernatant), or with different concentrations of recombinant IFN-7 (rlFN-7) or of PHA-activated mononuclear cell supernatant (PHA
supernatant). The relative fluorescence intensity is expressed on the ordinate, while the concentrations of rlFN-7 or PHA supernatant are
expressed on the abscissa.
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FIG. 2. Expression on human bronchial epithelial cells of ICAM-1 surface molecules after 24 h incubations with medium alone (control
supernatant), or with different concentrations of recombinant IFN-y (rlFN-y) or of PHA-activated mononuclear cell supernatant (PHA
supernatant). The relative fluorescence intensity is expressed on the ordinate, while the concentrations of rlFN-7 or PHA supernatant are
expressed on the abscissa.
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still statistically significant even at the lowest concen-
trations (p < 0.05, for all comparisons with BEC cul-
tures without drugs). A dose-dependent, significant
inhibition was also observed in cultures containing
dexamethasone (p < 0.05, for all comparisons with
BEC cultures without drugs). Nedocromil was more
effective than dexamethasone at the highest concen-
trations tested (10-4 to 10-
M), but the differences
were statistically significant only at 10-
M (p < 0.05).
The addition of both drugs to BEC cultures resulted
in a synergistic downregulating effect only at the
lowest concentrations tested, being statistically sig-
nificant at 10-7 to 10-9 M (p < 0.05).
Pharmacologic inhibition of ICAM-1 expression on
bronchial epithelial cells: When nedocromil and
dexamethasone were added to the bronchial cell
cultures together with the PHA-stimulated BMC
supernatant, they were only able to downregulate
ICAM-1 expression at concentrations between 10-4
and 10-7M (Fig. 4). In contrast with the effect which
had been observed on HLA-DR expression,
dexamethasone had a significantly stronger effect
when compared with nedocromil (p < 0.05) at all the
concentrations which had proved to be effective
(from 10-4 to 10-7 M). The two drugs together showed
a significant synergistic effect at doses ranging from
10-
to 10-9 M, and this was also observed at concen-
trations (10-8 to 10-9 M) which had proved ineffective
when both drugs were used alone (Fig. 4).
Discussion
In this study, using BEC primary cultures, we have
demonstrated that: (a) the expression of HLA-DR and
ICAM-1 molecules, on BEC can be upregulated by
supernatants from BMC-CM as well as by IFN-y; (b)
nedocromil sodium shows a dose-dependent inhibi-
tory effect on the expression of these activation
surface molecules, this effect being stronger on HLA-
DR than on ICAM-1 expression; (c) a similar dose-
dependent inhibitory effect is observed using
dexamethasone, which appears to be less active than
nedocromil on HLA-DR expression and more active
on ICAM-1 expression. HLA-DR molecules are
expressed on the surface of a wide variety of
cells belonging to the immune system, such as
B lymphocytes, dendritic cells, monocytes,
macrophages and activated T lymphocytes.
1-’ These
surface molecules have been shown to play a key
role in the interaction between antigen-presenting
cells and T-lymphocytes which occurs during recog-
nition of foreign antigens. In addition, HLA-DR mole-
cules can also be expressed by cells that are not part
of the immune system, such as endothelial cells and
some epithelial ceils, including human bronchial
epithelial cells. 21-23 Although the functional implica-
tion of the expression of HLA-DR molecules by
nonlymphoid tissues is not completely understood,
it has been hypothesized that, at least for some
organs, they might be involved in the active process
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FIG. 3. Inhibitory effects of nedocromil sodium i), dexamethasone( or nedocromil sodium plus dexamethasone (M) on the expression of HLA-DR
antigens by bronchial epithelial cells cultured for 24 h at 37C, 5% CO with 0.5% of supernatants from PHA-stimulated BMC. The percentage of inhibition
is expressed on the ordinate, while the different concentrations of nedocromil sodium and dexamethasone are expressed on the abscissa.
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FIG. 4. Inhibitory effects of nedocromil sodium i), demamethasone ), or nedocromil sodium plus dexamethasone (I-I) on the expression of ICAM-1 by
bronchial epithelial cells cultured for 24 h at 37C, 5% CO with 0.5% of supernatants from PHA-stimulated BMC. The percentage of inhibition is expressed
on the ordinate, while the different concentrations of nedocromil sodium and dexamethasone are expressed on the abscissa.
of antigen presentation and in the organization and
the recruitment of inflammatory and immune effector
cells. On the other hand, the ICAM-1 molecule be-
longs to the superfamily of the immunoglobulins
24
and acts as ligand for other (molecules expressed on
monocytes and lymphocytes (LFA-1), and on
neutrophils and eosinophils (Mac-l). 24,25 The expres-
sion of ICAM-1 is increased in sites of inflammatory
reactions in tissues26 and is associated with increased
polymorphonuclear leukocyte (PMN) adhesion and
activation. 27 Since PMN cytotoxicity is dependent, at
least in part, on adhesion of PMNs to target cells, it
is possible that this mechanism could be involved
in the damage to the respiratory epithelium that
is observed in airway inflammatory disorders
characterized by the presence of neutrophils
and eosinophils.
’6 Therefore, it appears that the
increased expression of HLA-DR and ICAM-1 may
represent a mechanism by which BECs adhere to
immunoeffector cells and deliver accessory signals.
These mechanisms could be required for further T-
cell activation, and for the recruitment of other cell
types involved in inflammatory reactions, such as
polymorphonuclear leukocytes and eosinophils.2<27
In this context, it has been recently demonstrated
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that HBEC from asthmatic subjects and from patients
with chronic bronchitis show increased ICAM-1 and
HLA-DR expression, and that the levels of this ex-
pression correlate with the gravity of the illness. The
concept that both asthma and chronic bronchitis are
characterized by the presence of activated mono-
nuclear cells in the airways, and the evidence that
activated BMC products activate BEC provided by the
present study, give further support to the hypothesis
that a complex cell-to-cell interaction occurs in
inflammatory disorders of the airways.
9,1
Since activated T-cells release great amounts of
IFN-T,
28 it is likely that this cytokine might have an
important role in stimulating the expression of HLA-
DR and ICAM-1 by bronchial epithelial cells. How-
ever, since HLA-DR expression is quite selectively
upregulated by IFN-T, while ICAM-1 molecules can
be induced by different cytokines (mainly TNF-ot and
IL-1, besides IFN-T), it is to be expected that a better
correlation exists between the concentrations of
BMC-CM and the relative fluorescence specific for
HLA-DR, than has been found between BMC-CM and
ICAM-1 as shown in the present study. It is also
interesting that, like dexamethasone, nedocromil
sodium, an anti-inflammatory drug used in the treat-Nedocromil sodium downregulates HLA-DR and ICAM-I expression
ment of asthma and chronic bronchitis, is effective in
downregulating the expression of HLA-DR and
ICAM-1 on bronchial epithelial cells. Nedocromil
sodium is thought to act on cells at the membrane
level, where it inhibits the release of secretory media-
tors. This function is mediated through the activity of
the drug on the C1- channels, resulting in stabilization
of the membrane. 29 It would be interesting to study
whether the inhibitory effect of nedocromil sodium
on the expression of HLA-DR and ICAM-1 on bron-
chial epithelial cells occurs not only at the cell mem-
brane level but also at a transcriptional level, as
demonstrated for corticosteroids.3 The results of the
present study demonstrate that it is possible to
upregulate in vitro the expression of inflammatory
markers on the BEC surface by the secretory products
of activated lymphocytes. These results also add new
insights into understanding the mechanisms that ini-
tiate and sustain the inflammatory processes in the
lungs, and into understanding the effect at the cellu-
lar level of a drug already used in the treatment of the
inflammatory reaction associated with asthma and
chronic bronchitis., The observation that nedocromil
and dexamethasone showed a sinergistic effect at the
lowest concentrations tested on the expression of
activation surface molecules by bronchial epithelial
cells supports the concept of the ’steroid sparing
effect’ of cromones.
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